Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy

Bo Hyun Kim, Joong-Won Park
Center for Liver Cancer, National Cancer Center, Goyang, Korea

INTRODUCTION

Systemic therapy for hepatocellular carcinoma (HCC) has markedly changed since 2007, with the approval of sorafenib. Sorafenib improved the overall survival of patients with advanced HCC; however, the modest efficacy and toxicity of this therapy present unmet needs. Subsequently, a variety of molecular targeted agents have been tested as first-line or second-line therapies but have failed, and sorafenib has remained the only approved systemic agent for almost 10 years. Recently, regorafenib significantly improved overall survival and was approved for patients with HCC who have been previously treated with sorafenib. Nivolumab, a programmed death protein-1 inhibitor, was also approved as second-line therapy, based on remarkable response rates. (J Liver Cancer 2018;18:17-22)

Keywords: Hepatocellular carcinoma; Molecular targeted therapy; Immunotherapy

MOLECULAR TARGETED THERAPY

1. Sorafenib

Sorafenib is an oral, multiple kinase inhibitor that blocks the platelet derived growth factor receptor (PDGFR), Raf kinase, and vascular endothelial growth receptor (VEGFR). Two multicenter randomized placebo-controlled phase III trials were conducted for patients with advanced HCC who had not received any prior systemic therapy in Europe and America.
(SHARP trial) and in the Asia-Pacific region.\(^7,8\) The SHARP trial demonstrated a significantly longer median overall survival (OS) duration of 10.7 months in patients receiving sorafenib, compared to an OS of 7.9 months for patients who received placebos (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.55–0.87; \(P<0.001\)).\(^7\) The disease control rate, defined as the percentage of patients who achieved complete response, partial response, and stable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria, was 43% in the sorafenib group compared with 32% in the placebo group (\(P=0.002\)). The partial response rate was only 2% in the sorafenib group, and no patients showed complete response. The Asia-Pacific trial also showed a significantly superior median OS of 6.5 months in patients receiving sorafenib, compared with 4.2 months in patients receiving placebos (HR, 0.57; 95% CI, 0.42–0.79; \(P=0.014\)).\(^8\) The most common adverse events were hand-foot syndrome, diarrhea, hair loss and fatigue.\(^7,8\) Sorafenib became the standard 1st-line therapy for advanced HCC through these two trials. Since then, substantial studies have attempted to predict patient responses to sorafenib; however, a clear conclusion has yet to be achieved.\(^9\)\(^-\)\(^11\)

2. Regorafenib

Regorafenib inhibits multiple protein kinases, including VEGFR and tyrosine kinase with immunoglobulin and epidermal growth factor homology domain (TIE). A randomized, double-blind, placebo-controlled phase 3 trial (RESORCE) enrolled 573 patients who progressed on sorafenib.\(^12\) Patients who had not tolerated sorafenib were excluded, because regorafenib and sorafenib have similar toxicity profiles. Enrolled patients were randomized, in a 2:1 ratio, to receive either regorafenib (160 mg) or placebo once daily, during weeks 1–3 of each 4-week cycle. The study met the primary endpoint of OS with a HR of 0.63 (95% CI, 0.50–0.79; one-sided \(P<0.001\)). The median patient survival durations were 10.6 months with regorafenib and 7.8 months with placebo.\(^12\) The disease control rate was 65% (complete response in 1% and partial response in 10%).\(^12\) The most common clinically-relevant grade 3 or 4 adverse events were hypertension (15%), hand-foot skin reaction (13%), fatigue (9%), and diarrhea (3%).\(^12\) Based on these results, regorafenib became the first approved second-line agent for advanced HCC. However, whether patients who were intolerant to sorafenib can tolerate and respond well to regorafenib remains unclear, because such patients were excluded from the RESORCE trial.

3. Lenvatinib

Lenvatinib is an oral, multi-kinase inhibitor that targets VEGFR, fibroblast growth factor receptor (FGFR), PDGFR alpha, rearranged during transfection gene (RET), and KIT. Lenvatinib is approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma. A total of 954 patients with advanced HCC who had not received systemic chemotherapy were randomized to receive either lenvatinib (body weight \(\geq 60\) kg: 12 mg/day; \(<60\) kg: 8 mg/day) or sorafenib (400 mg twice daily) in a 1:1 ratio.\(^13\) This noninferiority phase III trial (REFLECT) indicated that lenvatinib was noninferior to sorafenib in OS (13.6 months for lenvatinib vs. 12.3 months for sorafenib; HR, 0.92; 95% CI, 0.79–1.06).\(^13\) Furthermore, the median time to progression was significantly longer in patients receiving lenvatinib (7.4 months for lenvatinib vs. 3.7 months for sorafenib; HR, 0.63; 95% CI, 0.53–0.73; \(P<0.001\)).\(^13\) Objective response rates were also significantly higher (24% for lenvatinib vs. 9% for sorafenib; \(P<0.001\)), and the most common treatment-related adverse events of lenvatinib were hypertension, diarrhea, decreased appetite, and decreased weight. The approval of lenvatinib as a first-line agent for advanced HCC is anticipated.

4. Cabozantinib

Cabozantinib is an oral, multi-tyrosine kinase inhibitor that targets VEGFR, mesenchymal-epithelial transition (MET), growth arrest-specific 6 gene receptor (AXL), RET, KIT and FMS-like tyrosine kinase 3 (FLT3); however, cabozantinib has most potent activity against VEGFR and MET. A phase II trial was conducted for 41 patients with advanced HCC, all of whom had received up to one prior systemic anticancer therapy for more than four weeks before receiving an initial 12-week lead-in cabozantinib treatment.\(^14\) Patients with a partial
response could continue open-label cabozantinib, while pa-
tients with stable disease were randomized into either cabo-
zantinib or placebo cohorts, and patients with progressive dis-
ease discontinued therapy at or before week 12. At week 12,
two of the 41 patients achieved partial responses (5%), the dis-
ease control rate was 66%, and no patients showed complete
response.\textsuperscript{14}

A randomized, double-blind, placebo-controlled phase III
trial (CELESTIAL) enrolled 707 patients with advanced HCC
who had received up to two lines of prior systemic therapies
(including sorafenib) and progressed on at least one.\textsuperscript{15} Pa-
tients were randomized 2:1 to receive cabozantinib (60 mg)
or placebo once daily. At the second planned interim analysis,
the primary endpoint was met with longer OS in the cabozan-
tinib-treated group (10.2 months for cabozantinib vs. 8.0
months for placebo; HR, 0.76; 95% CI, 0.63–0.92; \( P=0.0049 \)).\textsuperscript{15}
The objective response rate was also significantly better in the
cabozantinib cohort (4% for cabozantinib vs. 0.4% for place-
bo, \( P=0.0086 \)).\textsuperscript{15} The most common grade 3/4 adverse events
were hand-foot skin reaction (17%) and hypertension (16%).\textsuperscript{15}
The response rate of 4% seems slightly lower compared to
other potential drugs; however, approval awaits.

5. Other agents

Tivantinib is an oral c-MET inhibitor. A randomized, place-
bo-controlled phase II study demonstrated that the median
time-to-progression was longer with tivantinib as second-line
therapy in patients with advanced HCC (1.6 months vs. 1.4
months; HR, 0.64; 95% CI, 0.43–0.94; \( P=0.04 \)).\textsuperscript{16} For patients
with high MET expression, the magnitude of the time-to-pro-
gression benefit when taking tivantinib was more significant
than in patients without high MET expression (2.7 months vs.
1.4 months; HR, 0.43; 95% CI, 0.19–0.97; \( P=0.03 \)).\textsuperscript{16} Therefore, a
randomized, placebo-controlled phase III trial was conducted for
MET-high patients who had shown progression or intolerance
while taking sorafenib; however, in this trial, tivantinib failed to
improve OS or progression-free-survival over placebo.\textsuperscript{17}

Ramucirumab is a recombinant immunoglobulin G 1
(IgG1) monoclonal antibody that binds to VEGFR-2 and is
approved for colorectal cancer, non-small cell lung cancer,
and gastric or gastroesophageal junction adenocarcinoma. A
randomized, placebo-controlled, phase III trial (REACH) for
patients with HCC who had previously received sorafenib
demonstrated that ramucirumab did not significantly im-
prove OS (9.2 months vs. 7.6 months; HR, 0.87; 95% CI,
0.72–1.05; \( P=0.14 \)).\textsuperscript{18} However, subgroup analysis suggested
that ramucirumab improved OS of patients with baseline al-
pha-fetoprotein levels \( \geq 400 \) ng/mL (7.8 months vs. 4.2
months; HR, 0.67; 95% CI 0.51–0.90). Currently, the
REACH-2 study of ramucirumab in patients with advanced
HCC with baseline alpha-fetoprotein levels of 400 ng/mL or
more is underway (NCT02435433).\textsuperscript{19}

IMMUNOTHERAPY

Immune checkpoints are co-inhibitory proteins that pre-
vent T cells from attacking other cells in the body. Immune
checkpoint inhibitors can release the brakes on the immune
system and restore the immune response against cancer cells.
Targets of immune checkpoint inhibitors include cytotoxic
T-lymphocyte protein 4 (CTLA-4), programmed cell death
protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1).

1. Nivolumab

Nivolumab is a humanized monoclonal IgG4 antibody to
human PD-1. A phase I/II, open-label dose escalation and ex-
ansion trial (CHECKMATE-040) was conducted for patients
with advanced HCC and included patients who experienced
disease progression while on at least one prior systemic thera-
py or who were intolerant of or refused sorafenib.\textsuperscript{20} The dose
escalation phase confirmed the manageable safety profile and
acceptable tolerability of nivolumab. At the dose expansion
phase, 214 patients with advanced HCC received intravenous
nivolumab at 3 mg/kg every 2 weeks.\textsuperscript{20} The objective response
and disease control rates were 20% and 64%, respectively (3
complete responses, 39 partial responses, and 96 stable diseas-
es).\textsuperscript{20} The 9-month overall survival rate was 74%,\textsuperscript{20} and grade
3 or 4 treatment-related adverse events were observed in 25%
(increased lipase in 13% and increased aspartate aminotrans-
ferase in 10%) of the patients.\textsuperscript{20} In 2017, the CHECKMATE-040
study enabled nivolumab to achieve accelerated approval for the treatment of HCC in patients who have been previously treated with sorafenib. This approval was based on the outstanding overall response (14.3%; 3 complete response and 19 partial response) and duration of response of a 154-patient subgroup who progressed on or were intolerant to sorafenib. Among the 22 responders, 91% had responses of six months or longer, and 55% had responses of 12 months or longer. A phase III trial of nivolumab versus sorafenib as first-line treatment is ongoing (CHECKMATE-459, NCT02576509).

2. Other immune checkpoint inhibitors

Pembrolizumab is an anti-PD-1 antibody that has been approved for melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, urothelial carcinoma, gastric cancer, and any solid tumor with high microsatellite instability or deficient mismatch repair. Pembrolizumab was the first approval based on a certain genetic feature, without regard to original tumor location. Recently, a phase II study of pembrolizumab (KEYNOTE-224) reported the efficacy and safety of this drug in patients with advanced HCC who were previously treated with sorafenib. Out of the 104 treated patients, one patient (1.0%), 16 (15.4%), and 47 (45.2%) showed complete response, partial response, and stable disease, respectively. The disease control rate was 61.5%, and the 6-month progression-free survival and overall survival rates were 43.1% and 77.9%, respectively. Of the responders, 94% had durable responses of six months or longer. Common adverse events included fatigue (21.2%) and increased aspartate aminotransferase levels (12.5%). Hepatitis B or hepatitis C virus flares were not observed when immune-mediated hepatitis occurred in 2.9% of the patients. A randomized, placebo-controlled phase III study of pembrolizumab as a second-line therapy for advanced HCC (KEYNOTE-240) is currently ongoing (NCT02702401), and promising results are anticipated.

Durvalumab is a human IgG1 monoclonal antibody that blocks the interactions of PD-L1 with PD-1 and CD80 and has been approved for urothelial carcinoma. Tremelimumab is a human monoclonal antibody against CTLA-4 that has been approved for malignant mesothelioma. Tremelimumab has shown a partial response rate of 17.6% and a disease control rate of 76.4% in patients with HCC and chronic hepatitis C virus infection. PD-1 and CTLA-4 have been suggested as non-redundant pathways for the regulation of T cell responses; and therefore, simultaneous inhibition of PD-1 and CTLA-4 pathways may have the potential for synergism. According to the results of a phase I part of a phase I/II, open-label, randomized study of durvalumab and tremelimumab for unresectable HCC, the response rate was 20% and the disease control rate at week 16 was 57.5% across 40 enrolled patients. A phase III trial of durvalumab and tremelimumab as first-line therapy is currently ongoing (NCT03298451).

ONGOING CLINICAL TRIALS

| Experimental | Comparator | Identifier |
|--------------|------------|------------|
| Nivolumab    | Sorafenib  | NCT02576509|
| Durvalumab ± tremelimumab | Sorafenib | NCT03298451|
| Vaccinia virus-based immunotherapy + sorafenib | Sorafenib | NCT02562755|
| Icaritin     | Sorafenib  | NCT03236649|
| BGB-A317     | Sorafenib  | NCT03412773|
| Pembrolizumab | Placebo   | NCT02702401 |
|              |            | NCT03062358|
| Ramucirumab  | Placebo    | NCT02435433|
| Apatinib     | Placebo    | NCT02329860|

HCC, hepatocellular carcinoma.
investigation. Phase III clinical trials of apatinib, a VEGFR-2 inhibitor, and vaccinia, a virus-based immunotherapy, are ongoing for patients with advanced HCC, as shown in Table 1.

CONCLUSIONS

In 2007, there was a breakthrough with sorafenib as a treatment for advanced HCC. These have been hard times, with many failures that may be attributable to heterogeneity of patient populations, deficits in trial designs, marginal antitumor activity of investigational drugs, or absence of biomarkers.28,29 Currently, we have two additional approved drugs (regorafenib and nivolumab) and another two with positive results in phase III trials (lenvatinib and cabozantinib), although none of these therapeutics have clear biomarkers. Molecular targeted agents have shown improved OS, with limited response rates. On the contrary, immune checkpoint inhibitors are drawing attention due to remarkable response rates and durable responses. Results based on conventional RECIST criteria alone may underestimate the efficacy of immune checkpoint inhibitors since pseudoprogression and immune-related patterns of mixed response have been reported.30 Immune checkpoint inhibitors might lead the way for future HCC therapies, and warrant further studies.

AUTHOR CONTRIBUTIONS

BH Kim and JW Park were responsible for the acquisition and interpretation of the data, and the drafting of the manuscript.

ACKNOWLEDGEMENT

This work was supported by National Cancer Center, Korea (NCC # 1510520).

Conflicts of Interest

The authors have no conflicts to disclose.

REFERENCES

1. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-4075.
2. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-566.
3. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
4. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
5. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67.
6. Cainap C, Qin S, Huang WT, Chung U, Pan H, Cheng Y, et al. Lini-fanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172-179.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
8. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
9. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-829.
10. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012;56:1080-1088.
11. Llovet JM, Peña CE, Lathe CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-2300.
12. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
13. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018 Feb 9. pii: S0140-6736(18)30207-1. doi: 10.1016/S0140-6736(18)30207-1. [Epub ahead of print].

14. Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017;28:528-534.

15. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial [Abstract]. J Clin Oncol 2018;36(15 suppl):207.

16. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63.

17. Rimassa L, Assenat E, Peck-Radosavljevic M, Zagonel V, Pracht M, Rota Caremoli E, et al. Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial [Abstract]. J Clin Oncol 2017;35(15 suppl):4000.

18. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-870.

19. Zhu AX, Galle PR, Kudo M, Finn R, Yang L, Abada P, et al. A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2) [Abstract]. Ann Oncol 2016;27(suppl 6):710TiP.

20. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502.

21. U.S. Food and Drug Administration. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib [Internet]. Silver Spring, MD (USA): U.S. Food and Drug Administration; [cited 2017 Jan 30]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577166.htm.

22. Sangro B, Park JW, Dela Cruz CM, Anderson J, Lang L, Neely J, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459 [Abstract]. J Clin Oncol 2016;34(15 suppl):TPS4147.

23. Zhu AX, Finn RS, Cattan S, Edeline J, Ogasawara S, Palmer DH, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib [Abstract]. J Clin Oncol 2017;35(4 suppl):TPS503.

24. Finn RS, Chan SL, Zhu AX, Knox JJ, Cheng AL, Siegel AB, et al. KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma [Abstract]. J Clin Oncol 2017;35(4 suppl):TPS510.

25. Sangro B, Gomez-Martín C, de la Mata M, Ilharraiaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimunab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-88.

26. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 2015;4:385.

27. Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, Yong WP, et al. Phase II/III study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses [Abstract]. J Clin Oncol 2017;35(15 suppl):4073.

28. Kim BH, Park JW. Systemic therapy for hepatocellular carcinoma: why do we keep failing? Hepatic Oncology 2014;1:355-358.

29. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014;20:2072-2079.

30. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3543.